AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Rivalry Corp.

$0 -$0.03 (-95.04%)
OTC · 14 Sep 2026 20:00 UTC
Previous Close
$0
Day Range
$0$0
Year Range
$0$0.45
Market Cap
148.36K
AVG Volume
3.22K
Trailing/Forward PE
-0.05/-
PEG ratio
0
Dividend Yield
-
Next Earnings Date
2026-11-26
Primary Exchange
Other OTCUS
Revenue (CAD)
02.5M5M7.5M10M23 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
RVLCF Revenue (CAD) by quarter
PeriodRevenue (CAD)
25 Q31.93M
25 Q21.62M
25 Q11.31M
24 Q41.44M
24 Q32.95M
24 Q24.65M
24 Q17.7M
23 Q46.46M
23 Q38.74M
23 Q28.5M
Net Income (CAD)
-10M-7.5M-5M-2.5M023 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
RVLCF Net Income (CAD) by quarter
PeriodNet Income (CAD)
25 Q3-1.96M
25 Q2-2.19M
25 Q1-2.99M
24 Q4-5.95M
24 Q3-5.89M
24 Q2-5.37M
24 Q1-5.2M
23 Q4-8.58M
23 Q3-5.64M
23 Q2-6.31M
Operating Income (CAD)
-8M-6M-4M-2M023 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
RVLCF Operating Income (CAD) by quarter
PeriodOperating Income (CAD)
25 Q3-1.6M
25 Q2-2M
25 Q1-2.68M
24 Q4-3.27M
24 Q3-5.52M
24 Q2-4.85M
24 Q1-5.06M
23 Q4-7.58M
23 Q3-5.27M
23 Q2-6.16M
EBITDA (CAD)
-8M-6M-4M-2M023 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
RVLCF EBITDA (CAD) by quarter
PeriodEBITDA (CAD)
25 Q3-921.05K
25 Q2-1.98M
25 Q1-2.41M
24 Q4-5.34M
24 Q3-5.36M
24 Q2-4.76M
24 Q1-5.02M
23 Q4-7.57M
23 Q3-5.58M
23 Q2-6.25M
Cash Flows (CAD)
-10M-7.5M-5M-2.5M02.5M23 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
RVLCF Cash Flows (CAD) by quarter
PeriodCash Flows (CAD)
25 Q394.41K
25 Q2-355.3K
25 Q1-1.79M
24 Q4-3.21M
24 Q3-694.11K
24 Q2-4.36M
24 Q1-3.56M
23 Q4-8.3M
23 Q3-4.73M
23 Q2-6.23M
EPS (CAD)
-0.15-0.1-0.05-023 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
RVLCF EPS (CAD) by quarter
PeriodEPS (CAD)
25 Q3-0.02
25 Q2-0.03
25 Q1-0.04
24 Q4-0.09
24 Q3-0.09
24 Q2-0.08
24 Q1-0.08
23 Q4-0.13
23 Q3-0.09
23 Q2-0.1
Expenses (CAD)
-5M05M10M15MR&DSG&ACapex23 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
RVLCF Expenses (CAD) by quarter
PeriodExpenses (CAD)
25 Q32.74M
25 Q23.56M
25 Q13.93M
24 Q44.74M
24 Q38.37M
24 Q29.5M
24 Q19.51M
23 Q410.47M
23 Q39.2M
23 Q29.95M
Cash & Debt (CAD)
05M10M15M20MCashLong Term DebtShort Term Debt23 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
RVLCF Cash & Debt (CAD) by quarter
PeriodCash & Debt (CAD)
25 Q3130.66K
25 Q2530.17K
25 Q1687.38K
24 Q41.57M
24 Q3139.11K
24 Q21.24M
24 Q19.37M
23 Q413.47M
23 Q33.73M
23 Q29.02M
Debt ratios
-2-1.5-1-0.500.523 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
RVLCF Debt ratios by quarter
PeriodDebt ratios
25 Q3-1.69
25 Q2-1.06
25 Q1-0.72
24 Q4-0.52
24 Q3-0.51
24 Q2-0.43
24 Q1-0.06
23 Q40.14
23 Q30.12
23 Q20.31
Margins
0%25%50%75%100%23 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
RVLCF Margins by quarter
PeriodMargins
25 Q3100%
25 Q2100%
25 Q1100%
24 Q4100%
24 Q3100%
24 Q2100%
24 Q157.42%
23 Q444.73%
23 Q345.36%
23 Q244.98%
Return on Capital
-250%0%250%500%750%1000%23 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
RVLCF Return on Capital by quarter
PeriodReturn on Capital
25 Q38.3%
25 Q210.34%
25 Q115.47%
24 Q435.43%
24 Q339.51%
24 Q259.8%
24 Q1149.76%
23 Q4775.35%
23 Q3-91.54%
23 Q2-53.26%
Shares Outstanding
020M40M60M80M23 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
RVLCF Shares Outstanding by quarter
PeriodShares Outstanding
25 Q367.08M
25 Q267.08M
25 Q167.26M
24 Q467.17M
24 Q365.12M
24 Q265.12M
24 Q165.06M
23 Q464.86M
23 Q361.86M
23 Q260.61M
Book Value Per Share (CAD)
-0.4-0.200.223 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
RVLCF Book Value Per Share (CAD) by quarter
PeriodBook Value Per Share (CAD)
25 Q3-0.35
25 Q2-0.32
25 Q1-0.29
24 Q4-0.25
24 Q3-0.23
24 Q2-0.14
24 Q1-0.05
23 Q4-0.02
23 Q30.1
23 Q20.2
Total Assets (CAD)
05M10M15M20M23 Q223 Q323 Q424 Q124 Q224 Q324 Q425 Q125 Q225 Q3
RVLCF Total Assets (CAD) by quarter
PeriodTotal Assets (CAD)
25 Q32M
25 Q22.47M
25 Q12.77M
24 Q44.09M
24 Q33.58M
24 Q26.12M
24 Q110.92M
23 Q415.08M
23 Q39.08M
23 Q215.86M
Free Cash Flow Yield
-4000%-3000%-2000%-1000%0%med -312.57%Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
RVLCF Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 26-3329.22%
Sep 26-3329.22%
Sep 26-2101.83%
Aug 26-2091.27%
Aug 26-1901.05%
Aug 26-1886.07%
Aug 26-1877.5%
Jul 26-1867.32%
Jul 26-1856.7%
Jul 26-2073.64%
Jul 26-2054.46%
Jul 26-2050.06%
Jun 26-2049.09%
Jun 26-2056.45%
Jun 26-2078.42%
Jun 26-2085.87%
May 26-903.7%
May 26-2185.32%
May 26-865.29%
May 26-869.74%
May 26-875.42%
Apr 26-870.32%
Apr 26-1398.59%
Apr 26-1418%
Apr 26-1409.96%
Mar 26-1412.76%
Mar 26-1430.44%
Mar 26-1330.47%
Mar 26-1346.27%
Feb 26-810.66%
Feb 26-717.58%
Feb 26-459.43%
Feb 26-213.3%
Jan 26-120.1%
Jan 26-105.1%
Jan 26-96.93%
Jan 26-141.6%
Jan 26-166.95%
Dec 25-191.35%
Dec 25-181.21%
Dec 25-125.56%
Dec 25-125.15%
Nov 25-258.4%
Nov 25-256.08%
Nov 25-257.52%
Nov 25-257.03%
Oct 25-257.83%
Oct 25-260.07%
Oct 25-259.62%
Oct 25-260.01%
Oct 25-260.97%
Sep 25-432.59%
Sep 25-437.82%
Sep 25-434.49%
Sep 25-435.12%
Aug 25-322.03%
Aug 25-320.11%
Aug 25-320.26%
Aug 25-289.92%
Aug 25-286.93%
Jul 25-288.81%
Jul 25-155.72%
Jul 25-430.2%
Jul 25-433.45%
Jun 25-506.92%
Jun 25-504.91%
Jun 25-510.63%
Jun 25-506.53%
May 25-404.48%
May 25-404.7%
May 25-397.8%
May 25-398.81%
May 25-305.04%
Apr 25-274.67%
Apr 25-274.98%
Apr 25-2228.73%
Apr 25-176.85%
Mar 25-259.3%
Mar 25-258.62%
Mar 25-258.26%
Mar 25-258.4%
Feb 25-256.67%
Feb 25-261.07%
Feb 25-261.72%
Feb 25-259.78%
Jan 25-255.54%
Jan 25-258.8%
Jan 25-256.32%
Jan 25-257.43%
Jan 25-256.95%
Dec 24-223.33%
Dec 24-203.22%
Dec 24-216.65%
Dec 24-273.01%
Nov 24-229.87%
Nov 24-225.81%
Nov 24-224.02%
Nov 24-272.94%
Nov 24-138.44%
Oct 24-139%
Price to Sales
00.250.50.751med 0.27Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
RVLCF Price to Sales by quarter
PeriodPrice to Sales
Sep 260.03
Sep 260.03
Sep 260.04
Aug 260.04
Aug 260.04
Aug 260.04
Aug 260.04
Jul 260.04
Jul 260.05
Jul 260.04
Jul 260.04
Jul 260.04
Jun 260.04
Jun 260.04
Jun 260.04
Jun 260.04
May 260.09
May 260.04
May 260.1
May 260.1
May 260.1
Apr 260.1
Apr 260.06
Apr 260.06
Apr 260.06
Mar 260.06
Mar 260.06
Mar 260.06
Mar 260.06
Feb 260.1
Feb 260.12
Feb 260.18
Feb 260.39
Jan 260.7
Jan 260.8
Jan 260.86
Jan 260.59
Jan 260.5
Dec 250.43
Dec 250.46
Dec 250.66
Dec 250.66
Nov 250.32
Nov 250.32
Nov 250.32
Nov 250.32
Oct 250.32
Oct 250.32
Oct 250.32
Oct 250.32
Oct 250.32
Sep 250.22
Sep 250.22
Sep 250.22
Sep 250.22
Aug 250.3
Aug 250.3
Aug 250.3
Aug 250.34
Aug 250.34
Jul 250.34
Jul 250.62
Jul 250.23
Jul 250.22
Jun 250.14
Jun 250.14
Jun 250.14
Jun 250.14
May 250.17
May 250.17
May 250.18
May 250.18
May 250.23
Apr 250.26
Apr 250.26
Apr 250.03
Apr 250.4
Mar 250.3
Mar 250.3
Mar 250.3
Mar 250.3
Feb 250.3
Feb 250.3
Feb 250.3
Feb 250.3
Jan 250.3
Jan 250.3
Jan 250.3
Jan 250.3
Jan 250.3
Dec 240.34
Dec 240.37
Dec 240.35
Dec 240.28
Nov 240.33
Nov 240.34
Nov 240.34
Nov 240.28
Nov 240.55
Oct 240.55
Price/Operating Cashflow
810121416med 11.39Sep 22Oct 22Oct 22Nov 22Nov 22Dec 22Dec 22
RVLCF Price/Operating Cashflow by quarter
PeriodPrice/Operating Cashflow
Dec 2210.65
Dec 2211.39
Dec 2213.24
Dec 2213.63
Nov 229.6
Nov 229.61
Nov 229.95
Nov 229.92
Oct 2210.31
Oct 2212.24
Oct 2211.47
Oct 2214.47
Sep 2215.62
Price to Book
02.557.51012.5med 3.27Jun 22Sep 22Jan 23Apr 23Aug 23Nov 23Mar 24
RVLCF Price to Book by quarter
PeriodPrice to Book
Mar 2410.2
Mar 2410.88
Feb 2411.44
Feb 2410.69
Feb 2410.8
Feb 2410.25
Jan 2410.24
Jan 2410.22
Jan 2410.89
Jan 2410.72
Dec 239.83
Dec 235.02
Dec 235
Dec 236.09
Dec 236.71
Nov 234.71
Nov 234.74
Nov 235.2
Nov 235.31
Oct 234.75
Oct 238
Oct 237.96
Oct 237.96
Sep 238.19
Sep 239.49
Sep 239.52
Sep 239.46
Sep 239.64
Aug 238.78
Aug 237.38
Aug 237.32
Aug 237.28
Jul 237.21
Jul 237.48
Jul 237.47
Jul 237.37
Jun 237.49
Jun 236.07
Jun 236.07
Jun 236.19
May 236.32
May 236.32
May 236.35
May 236.26
Apr 236.34
Apr 236.34
Apr 236.26
Apr 236.32
Mar 236.33
Mar 232.63
Mar 233.26
Mar 233.28
Mar 233.23
Feb 233.23
Feb 233.2
Feb 233.17
Feb 233.18
Jan 233.16
Jan 232.47
Jan 232.33
Jan 232.34
Dec 222.35
Dec 221.72
Dec 221.84
Dec 222.14
Dec 222.2
Nov 221.55
Nov 221.55
Nov 221.61
Nov 221.6
Oct 221.66
Oct 221.98
Oct 221.85
Oct 222.34
Sep 222.52
Sep 222.03
Sep 222.73
Sep 222.68
Sep 222.7
Aug 221.77
Aug 221.61
Aug 221.86
Aug 221.88
Jul 221.86
Jul 221.88
Jul 221.89
Jul 221.88
Jul 221.87
Jun 221.57
Jun 221.72
Jun 222
Jun 221.99
May 222.01
May 221.9
May 221.91
May 222.54
Apr 222.53
Apr 222.5
Apr 222.46
Apr 222.47
Rivalry Corp.
RVLCF
Stockpicker

Video analysis: RVLCF

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: RVLCF

AMX Falls 11.1% in 3 Months Amid Brazil Rivalry and Currency Risks

zacks.com · 11 Aug 2026

AMX Falls 11.1% in 3 Months Amid Brazil Rivalry and Currency Risks

America Movil's 11.1% slide contrasts with firm postpaid and broadband growth, while Brazil competition and FX pressure cloud the outlook.

US-China AI Rivalry Grows With Alibaba's Anthropic Rival

youtube.com · 4 Aug 2026

US-China AI Rivalry Grows With Alibaba's Anthropic Rival

New Chinese AI models including Alibaba's flagship system that claims performance similar to Anthropic's Fable is intensifying the rivalry between China and the US over AI. Bloomberg's Minmin Low has the latest.

Amazon Narrows AI Ambitions as Retail Rivalry Intensifies

pymnts.com · 30 Jul 2026

Amazon Narrows AI Ambitions as Retail Rivalry Intensifies

Amazon's decision this week to scale back parts of its homegrown artificial intelligence portfolio has been taken by the marketplace as a retreat from the frontier-model competition. That's only partly true.

Novo Nordisk's Wegovy Pill Escalates Eli Lilly Rivalry

seekingalpha.com · 9 Jul 2026

Novo Nordisk's Wegovy Pill Escalates Eli Lilly Rivalry

Novo Nordisk regains competitive ground in obesity with the strong launch of the Wegovy pill, reversing some of the recent underperformance against Eli Lilly. NVO's Wegovy pill outpaces Eli Lilly's Foundayo in new-to-brand prescriptions, driven by superior weight loss efficacy and fewer drug interaction restrictions. Despite setbacks, NVO is advancing late-stage candidates like CagriSema, UBT251, and zenagamtide, aiming to rival Eli Lilly's next-generation assets by the early 2030s.

Circle Internet Group Faces New Stablecoin Rivalry From Open USD: What Investors Need to Know

benzinga.com · 1 Jul 2026

Circle Internet Group Faces New Stablecoin Rivalry From Open USD: What Investors Need to Know

Circle Internet Group Inc (NYSE:CRCL) shares are trading higher by almost 2% during Wednesday's premarket session as traders weigh renewed stablecoin competition headlines.

Recurring Revenues & Buyouts Aid Broadridge Amid High Rivalry

zacks.com · 23 Jun 2026

Recurring Revenues & Buyouts Aid Broadridge Amid High Rivalry

BR benefits from recurring SaaS revenues, acquisitions and strong shareholder returns, but competition and liquidity risks remain.

World Cup's Off-Pitch Rivalry Pits Adidas And Nike For Football Dominance

forbes.com · 17 Jun 2026

World Cup's Off-Pitch Rivalry Pits Adidas And Nike For Football Dominance

The 2026 FIFA World Cup is set to be the most competitive since its founding nearly a century ago—more teams, more games and a global audience waiting to see which two teams reach the final on July 19. Yet even before the tournament began, two fierce competitors were already battling it out for dominance in the world's most popular sport: Adidas and Nike.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.